Recent federal actions have advanced partial cannabis rescheduling while leaving full reclassification from Schedule I to Schedule III unresolved. In late April 2026 the Department of Justice and DEA issued an order moving FDA-approved marijuana products and state-licensed medical cannabis to Schedule III, with the change effective upon Federal Register publication. The same announcement launched an expedited administrative hearing on broader rescheduling that begins June 29, 2026, and is scheduled to conclude by mid-July. These steps responded to a December 2025 executive order directing expedited review, yet the hearing timeline and potential appeals or further rulemaking mean any final decision on nationwide rescheduling remains months away. Traders therefore price modest odds for completion by year-end, reflecting both the procedural momentum and remaining legal and administrative hurdles.
Експериментальне резюме, згенероване ШІ з посиланням на дані Polymarket. Це не торгова порада і не впливає на вирішення цього ринку. · Оновлено$758,577 Обс.
June 30
1%
December 31
24%
$758,577 Обс.
June 30
1%
December 31
24%
The primary resolution source for this market will be official information from the US government, however a consensus of credible reporting will also be used.
Ринок відкрито: Feb 7, 2026, 5:04 PM ET
Resolver
0x65070BE91...The primary resolution source for this market will be official information from the US government, however a consensus of credible reporting will also be used.
Resolver
0x65070BE91...Recent federal actions have advanced partial cannabis rescheduling while leaving full reclassification from Schedule I to Schedule III unresolved. In late April 2026 the Department of Justice and DEA issued an order moving FDA-approved marijuana products and state-licensed medical cannabis to Schedule III, with the change effective upon Federal Register publication. The same announcement launched an expedited administrative hearing on broader rescheduling that begins June 29, 2026, and is scheduled to conclude by mid-July. These steps responded to a December 2025 executive order directing expedited review, yet the hearing timeline and potential appeals or further rulemaking mean any final decision on nationwide rescheduling remains months away. Traders therefore price modest odds for completion by year-end, reflecting both the procedural momentum and remaining legal and administrative hurdles.
Експериментальне резюме, згенероване ШІ з посиланням на дані Polymarket. Це не торгова порада і не впливає на вирішення цього ринку. · Оновлено
Обережно з зовнішніми посиланнями.
Обережно з зовнішніми посиланнями.
Часті запитання